US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

61.00

-0.4200-0.68%

Volume:8K

Turnover:518.02K

Market Cap:2.94B

PE:-25.36

High:61.00

Open:61.00

Low:61.00

Close:61.42

52wk High:72.64

52wk Low:9.63

Shares:48.16M

Float Shares:27.63M

Volume Ratio:8.78

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.4052

EPS(LYR):-2.3824

ROE:-33.17%

ROA:-22.08%

PB:7.17

PE(LYR):-25.60

Loading ...

Overview Company News Filings

A Look At MBX Biosciences (MBX) Valuation After Recent Share Price Pullback

Simply Wall St.

Stock Track | MBX Biosciences Plummets 5.08% Intraday on Negative Earnings Expectations

MBX Biosciences Inc expected to post a loss of 58 cents a share - Earnings Preview

MBX Biosciences Inc. publishes corporate presentation on endocrine and metabolic peptide drug development pipeline

Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss

MT Newswires Live

MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate

Benzinga Earnings

MBX Biosciences FY 2025 net loss rose 40% to USD 86.97 million, while G&A expenses jumped 75% to USD 18.9 million

Press Release: MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

Mbx Biosciences Appoints Karen Basbaum as Chief Business Officer

THOMSON REUTERS

Press Release: MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

Microbix Advances Modernized Manufacturing for Kinlytic Clot-Buster Drug

MBX Biosciences plans Q3 2026 Phase 3 trial for once-weekly canvuparatide in hypoparathyroidism

Mbx Biosciences Inc - to Initiate Phase 3 Trial for Canvuparatide in Q3 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/MBX/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":61,"timestamp":1788528601016,"preClose":61.42,"halted":0,"volume":8492,"delay":0,"changeRate":-0.006838163464669516,"floatShares":27629899,"shares":48160096,"eps":-2.4052,"marketStatus":"Trading","change":-0.42,"latestTime":"09-04 09:30:16 EDT","open":61,"high":61,"low":61,"amount":518017.47734,"amplitude":0,"askPrice":62.17,"askSize":114,"bidPrice":61,"bidSize":147,"shortable":3,"etf":0,"ttmEps":-2.4052,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788552000000},"marketStatusCode":2,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":61.42,"preHourTrading":{"tag":"盘前","latestPrice":60.96,"preClose":61.42,"latestTime":"09:29 EDT","volume":1134,"amount":69620.94342,"timestamp":1788528599999,"change":-0.46,"changeRate":-0.007489,"amplitude":0.045262},"postHourTrading":{"tag":"盘后","latestPrice":61.42,"preClose":61.42,"latestTime":"19:36 EDT","volume":14536,"amount":892802.74,"timestamp":1788478618540,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":8.775596,"impliedVol":1.0252,"impliedVolPercentile":0.741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":27629899,"roa":"-22.08%","roe":"-33.17%","lyrEps":-2.382369,"volumeRatio":8.775596,"shares":48160096,"dividePrice":0,"high":61,"amplitude":0,"preClose":61.42,"low":61,"week52Low":9.63,"pbRate":"7.17","week52High":72.64,"institutionHeld":0,"latestPrice":61,"committee":0.126437,"eps":-2.4052,"divideRate":0,"volume":8492,"delay":0,"ttmEps":-2.4052,"open":61,"prevYearClose":31.54,"prevWeekClose":63,"prevMonthClose":61.6,"prevQuarterClose":55.2,"fiveDayClose":63,"twentyDayClose":67.82,"sixtyDayClose":30.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"MBX","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2026-05-07","symbol":"MBX","fiscalQuarterEnding":"2026/03","expectedEps":-0.62,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2026-03-12","symbol":"MBX","fiscalQuarterEnding":"2025/12","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":-0.49},{"market":"US","date":"2025-11-06","symbol":"MBX","fiscalQuarterEnding":"2025/09","expectedEps":-0.73,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.63},{"market":"US","date":"2025-08-07","symbol":"MBX","fiscalQuarterEnding":"2025/06","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.58}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":12,"updateTime":1787371200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2026-09-03","current":-25.361716,"percent":0.092929,"low":-38.854907,"twenty":-19.051466,"median":-13.691869,"eighty":-5.76189,"high":-3.125337,"avg":-13.808037,"sd":8.272776,"marketCap":2932468245},"quantilePoints":[{"date":"2024-09-13","current":-15.960592,"twenty":-13.895501,"median":-10.797864,"eighty":-10.797864,"marketCap":753339957},{"date":"2024-09-20","current":-15.949203,"twenty":-15.694582,"median":-15.111074,"eighty":-12.419885,"marketCap":752802389},{"date":"2024-09-27","current":-16.939398,"twenty":-16.33255,"median":-15.751164,"eighty":-14.917986,"marketCap":799539567},{"date":"2024-10-04","current":-16.797941,"twenty":-16.986079,"median":-16.110499,"eighty":-15.091977,"marketCap":792862827},{"date":"2024-10-11","current":-16.932325,"twenty":-16.986079,"median":-16.31699,"eighty":-15.248994,"marketCap":799205730},{"date":"2024-10-18","current":-17.024271,"twenty":-17.032759,"median":-16.518565,"eighty":-15.369232,"marketCap":803545610},{"date":"2024-10-25","current":-15.022664,"twenty":-17.021442,"median":-16.380645,"eighty":-15.369232,"marketCap":709069745},{"date":"2024-11-01","current":-15.885548,"twenty":-16.991737,"median":-16.362963,"eighty":-15.369232,"marketCap":749797857},{"date":"2024-11-08","current":-13.874718,"twenty":-16.947885,"median":-16.309917,"eighty":-15.248994,"marketCap":765593046},{"date":"2024-11-15","current":-10.66494,"twenty":-16.936569,"median":-16.143706,"eighty":-14.480386,"marketCap":588480730},{"date":"2024-11-22","current":-11.203941,"twenty":-16.918179,"median":-15.949203,"eighty":-13.805677,"marketCap":618222233},{"date":"2024-11-29","current":-12.318278,"twenty":-16.877157,"median":-15.751164,"eighty":-12.380051,"marketCap":679710282},{"date":"2024-12-06","current":-13.432616,"twenty":-16.771064,"median":-15.461179,"eighty":-11.837418,"marketCap":741198331},{"date":"2024-12-13","current":-11.470413,"twenty":-16.663558,"median":-15.31265,"eighty":-11.837418,"marketCap":632925896},{"date":"2024-12-20","current":-12.330391,"twenty":-16.662143,"median":-15.019127,"eighty":-11.803503,"marketCap":680378630},{"date":"2024-12-27","current":-12.154761,"twenty":-16.656485,"median":-14.542475,"eighty":-11.803503,"marketCap":670687579},{"date":"2025-01-03","current":-11.258446,"twenty":-16.435813,"median":-14.054537,"eighty":-11.676323,"marketCap":621229800},{"date":"2025-01-10","current":-8.290916,"twenty":-16.380645,"median":-13.850493,"eighty":-11.492215,"marketCap":457484452},{"date":"2025-01-17","current":-5.989566,"twenty":-16.372157,"median":-13.75965,"eighty":-11.117943,"marketCap":330498264},{"date":"2025-01-24","current":-6.510398,"twenty":-16.36367,"median":-13.256987,"eighty":-10.797864,"marketCap":359237243},{"date":"2025-01-31","current":-6.06224,"twenty":-16.342452,"median":-12.878476,"eighty":-9.893382,"marketCap":334508354},{"date":"2025-02-07","current":-7.473331,"twenty":-16.314161,"median":-12.457571,"eighty":-8.809325,"marketCap":412370938},{"date":"2025-02-14","current":-6.304488,"twenty":-16.290113,"median":-12.324334,"eighty":-7.444262,"marketCap":347875321},{"date":"2025-02-21","current":-6.589128,"twenty":-16.247676,"median":-12.215323,"eighty":-7.171733,"marketCap":363581507},{"date":"2025-02-28","current":-5.813937,"twenty":-16.175534,"median":-12.009413,"eighty":-6.798672,"marketCap":320807212},{"date":"2025-03-07","current":-5.989566,"twenty":-16.064646,"median":-11.803503,"eighty":-6.591551,"marketCap":330498264},{"date":"2025-03-14","current":-5.26888,"twenty":-15.958314,"median":-11.682379,"eighty":-6.514032,"marketCap":290731536},{"date":"2025-03-21","current":-4.258879,"twenty":-15.936472,"median":-11.549143,"eighty":-6.294798,"marketCap":263718287},{"date":"2025-03-28","current":-4.188707,"twenty":-15.858671,"median":-11.258446,"eighty":-6.213645,"marketCap":259373118},{"date":"2025-04-04","current":-3.260282,"twenty":-15.749749,"median":-11.107042,"eighty":-6.057395,"marketCap":201883200},{"date":"2025-04-11","current":-3.999783,"twenty":-15.687509,"median":-10.797864,"eighty":-5.922948,"marketCap":247674589},{"date":"2025-04-17","current":-4.113138,"twenty":-15.461179,"median":-10.66494,"eighty":-5.686757,"marketCap":254693707},{"date":"2025-04-25","current":-4.949799,"twenty":-15.461179,"median":-9.901861,"eighty":-5.438453,"marketCap":306501482},{"date":"2025-05-02","current":-6.477382,"twenty":-15.454106,"median":-9.653557,"eighty":-5.327647,"marketCap":401092452},{"date":"2025-05-09","current":-5.996976,"twenty":-15.31265,"median":-8.539219,"eighty":-5.438453,"marketCap":371344761},{"date":"2025-05-16","current":-5.077465,"twenty":-15.206557,"median":-7.473331,"eighty":-5.077465,"marketCap":373015980},{"date":"2025-05-23","current":-5.691675,"twenty":-15.022664,"median":-7.246225,"eighty":-5.226487,"marketCap":418138881},{"date":"2025-05-30","current":-5.787218,"twenty":-15.017006,"median":-7.134185,"eighty":-5.260401,"marketCap":425157999},{"date":"2025-06-06","current":-5.395944,"twenty":-14.885451,"median":-6.813207,"eighty":-5.315894,"marketCap":396413040},{"date":"2025-06-13","current":-4.877278,"twenty":-14.35621,"median":-6.707223,"eighty":-5.172099,"marketCap":358309257},{"date":"2025-06-20","current":-4.677092,"twenty":-14.130289,"median":-6.595185,"eighty":-5.059804,"marketCap":343602533},{"date":"2025-06-27","current":-5.136611,"twenty":-14.052953,"median":-6.564904,"eighty":-5.017962,"marketCap":377361148},{"date":"2025-07-03","current":-5.673476,"twenty":-13.977856,"median":-6.515167,"eighty":-5.013234,"marketCap":416801906},{"date":"2025-07-11","current":-5.641628,"twenty":-13.855338,"median":-6.4303,"eighty":-5.035235,"marketCap":414462200},{"date":"2025-07-18","current":-5.548359,"twenty":-13.804466,"median":-6.320845,"eighty":-5.055522,"marketCap":407610204},{"date":"2025-07-25","current":-5.928259,"twenty":-13.766918,"median":-6.298431,"eighty":-5.072006,"marketCap":435519554},{"date":"2025-08-01","current":-6.028352,"twenty":-13.628836,"median":-6.310434,"eighty":-5.101123,"marketCap":442872915},{"date":"2025-08-08","current":-4.830149,"twenty":-13.362364,"median":-6.283291,"eighty":-5.101123,"marketCap":372013249},{"date":"2025-08-15","current":-5.76189,"twenty":-13.198847,"median":-6.22399,"eighty":-5.101123,"marketCap":443774969},{"date":"2025-08-22","current":-6.171895,"twenty":-13.089836,"median":-6.221845,"eighty":-5.14935,"marketCap":475353203},{"date":"2025-08-29","current":-6.224236,"twenty":-12.914207,"median":-6.224236,"eighty":-5.170279,"marketCap":479384467},{"date":"2025-09-05","current":-5.635398,"twenty":-12.685283,"median":-6.241684,"eighty":-5.176649,"marketCap":434032748},{"date":"2025-09-12","current":-4.331231,"twenty":-12.593229,"median":-6.221845,"eighty":-5.070186,"marketCap":333587089},{"date":"2025-09-19","current":-4.392296,"twenty":-12.449092,"median":-6.213645,"eighty":-5.008506,"marketCap":338290230},{"date":"2025-09-26","current":-10.057984,"twenty":-12.39822,"median":-6.217295,"eighty":-5.008506,"marketCap":774655869},{"date":"2025-10-03","current":-9.721364,"twenty":-12.327968,"median":-6.224236,"eighty":-5.029502,"marketCap":748729706},{"date":"2025-10-10","current":-9.207959,"twenty":-12.309799,"median":-6.253122,"eighty":-5.039662,"marketCap":709187798},{"date":"2025-10-17","current":-7.994552,"twenty":-12.25166,"median":-6.280939,"eighty":-5.051241,"marketCap":615732407},{"date":"2025-10-24","current":-9.364715,"twenty":-12.13417,"median":-6.307461,"eighty":-5.070186,"marketCap":721260982},{"date":"2025-10-31","current":-12.650784,"twenty":-12.13417,"median":-6.352937,"eighty":-5.089294,"marketCap":974350701},{"date":"2025-11-07","current":-13.743232,"twenty":-12.309799,"median":-6.369154,"eighty":-5.142981,"marketCap":1106261420},{"date":"2025-11-14","current":-13.426901,"twenty":-12.512852,"median":-6.477382,"eighty":-5.169369,"marketCap":1080798409},{"date":"2025-11-21","current":-15.07807,"twenty":-12.739549,"median":-6.521866,"eighty":-5.176649,"marketCap":1213709223},{"date":"2025-11-28","current":-19.239461,"twenty":-13.256987,"median":-6.567932,"eighty":-5.191208,"marketCap":1548680395},{"date":"2025-12-05","current":-17.036043,"twenty":-13.72255,"median":-6.589128,"eighty":-5.211681,"marketCap":1371316303},{"date":"2025-12-12","current":-15.859028,"twenty":-13.826268,"median":-6.619611,"eighty":-5.226487,"marketCap":1276572445},{"date":"2025-12-19","current":-15.992906,"twenty":-14.046615,"median":-6.70403,"eighty":-5.26888,"marketCap":1287348998},{"date":"2025-12-26","current":-17.911832,"twenty":-14.268105,"median":-6.806351,"eighty":-5.279538,"marketCap":1441812917},{"date":"2026-01-02","current":-17.59387,"twenty":-14.917986,"median":-6.813207,"eighty":-5.295223,"marketCap":1416218605},{"date":"2026-01-09","current":-17.136452,"twenty":-15.146199,"median":-7.076651,"eighty":-5.307262,"marketCap":1379398717},{"date":"2026-01-16","current":-22.820712,"twenty":-15.452731,"median":-7.200803,"eighty":-5.317689,"marketCap":1836953174},{"date":"2026-01-23","current":-23.646296,"twenty":-15.472295,"median":-7.424882,"eighty":-5.324948,"marketCap":1903408581},{"date":"2026-01-30","current":-20.550355,"twenty":-15.847871,"median":-7.61062,"eighty":-5.334947,"marketCap":1654200805},{"date":"2026-02-06","current":-20.109671,"twenty":-15.97998,"median":-7.994552,"eighty":-5.365916,"marketCap":1618727987},{"date":"2026-02-13","current":-22.260078,"twenty":-16.085028,"median":-8.265761,"eighty":-5.405044,"marketCap":1791824944},{"date":"2026-02-20","current":-21.826592,"twenty":-16.300015,"median":-8.354645,"eighty":-5.422333,"marketCap":1756931510},{"date":"2026-02-27","current":-20.526135,"twenty":-16.365085,"median":-8.65641,"eighty":-5.437203,"marketCap":1652251211},{"date":"2026-03-06","current":-18.414356,"twenty":-16.656674,"median":-8.777334,"eighty":-5.439664,"marketCap":1482263608},{"date":"2026-03-13","current":-15.268438,"twenty":-16.663558,"median":-8.888641,"eighty":-5.448143,"marketCap":1327911291},{"date":"2026-03-20","current":-15.530651,"twenty":-16.662191,"median":-9.207959,"eighty":-5.4632,"marketCap":1350716208},{"date":"2026-03-27","current":-15.454172,"twenty":-16.656674,"median":-9.44019,"eighty":-5.477809,"marketCap":1344064774},{"date":"2026-04-02","current":-17.639279,"twenty":-16.656721,"median":-9.686541,"eighty":-5.527885,"marketCap":1534105746},{"date":"2026-04-10","current":-17.950657,"twenty":-16.797941,"median":-9.847355,"eighty":-5.527885,"marketCap":1561186584},{"date":"2026-04-17","current":-18.147317,"twenty":-16.939398,"median":-9.944254,"eighty":-5.546084,"marketCap":1578290272},{"date":"2026-04-24","current":-18.240184,"twenty":-16.993812,"median":-10.091627,"eighty":-5.548359,"marketCap":1586367013},{"date":"2026-05-01","current":-16.529418,"twenty":-17.017199,"median":-10.162452,"eighty":-5.565633,"marketCap":1437580056},{"date":"2026-05-08","current":-19.051466,"twenty":-17.024271,"median":-10.419594,"eighty":-5.573382,"marketCap":1651171534},{"date":"2026-05-15","current":-19.432949,"twenty":-17.098465,"median":-10.797864,"eighty":-5.623429,"marketCap":1683048872},{"date":"2026-05-22","current":-17.470969,"twenty":-17.116218,"median":-10.949581,"eighty":-5.635398,"marketCap":1513125669},{"date":"2026-05-29","current":-17.531422,"twenty":-17.244113,"median":-11.182744,"eighty":-5.640382,"marketCap":1518361398},{"date":"2026-06-05","current":-16.987343,"twenty":-17.244113,"median":-11.332873,"eighty":-5.647113,"marketCap":1471239837},{"date":"2026-06-12","current":-20.471645,"twenty":-17.244113,"median":-11.549143,"eighty":-5.650278,"marketCap":1773008216},{"date":"2026-06-18","current":-22.856798,"twenty":-17.305607,"median":-11.667238,"eighty":-5.653457,"marketCap":1979581522},{"date":"2026-06-26","current":-27.68206,"twenty":-17.435508,"median":-11.803503,"eighty":-5.659497,"marketCap":2397487888},{"date":"2026-07-02","current":-30.732198,"twenty":-17.480357,"median":-11.965702,"eighty":-5.666777,"marketCap":2661654213},{"date":"2026-07-10","current":-36.112531,"twenty":-17.527026,"median":-11.991245,"eighty":-5.673476,"marketCap":3127634090},{"date":"2026-07-17","current":-32.051177,"twenty":-17.634503,"median":-12.154761,"eighty":-5.678788,"marketCap":2775888299},{"date":"2026-07-24","current":-34.936442,"twenty":-17.867538,"median":-12.324334,"eighty":-5.688724,"marketCap":3025775363},{"date":"2026-07-31","current":-36.524712,"twenty":-17.911832,"median":-12.436374,"eighty":-5.691675,"marketCap":3163332242},{"date":"2026-08-07","current":-30.628146,"twenty":-17.994359,"median":-12.627144,"eighty":-5.692585,"marketCap":3194270640},{"date":"2026-08-14","current":-30.97629,"twenty":-18.158049,"median":-12.72465,"eighty":-5.698044,"marketCap":3230579239},{"date":"2026-08-21","current":-30.63919,"twenty":-18.368939,"median":-13.111638,"eighty":-5.710784,"marketCap":3195422369},{"date":"2026-08-28","current":-30.657661,"twenty":-18.452139,"median":-13.429759,"eighty":-5.738476,"marketCap":3197348773},{"date":"2026-09-03","current":-28.117864,"twenty":-19.051466,"median":-13.691869,"eighty":-5.76189,"marketCap":2932468245}],"updateTime":1788528616345},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619946424","title":"A Look At MBX Biosciences (MBX) Valuation After Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2619946424","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619946424?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:11","pubTimestamp":1773666693,"startTime":"0","endTime":"0","summary":"Why MBX Biosciences is on investors’ radar today\nMBX Biosciences (MBX) has attracted attention after a recent move in its share price, with the stock now around $28 following mixed short term returns, including a decline over the past month and a modest gain over the past 3 months.\nSee our latest analysis for MBX Biosciences.\nThat recent pullback, with a 30 day share price return of around 26% decline and year to date share price return of around 8% decline, contrasts sharply with a very...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/a-look-at-mbx-biosciences-mbx-valuation-after-recent-share-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/a-look-at-mbx-biosciences-mbx-valuation-after-recent-share-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151954255","title":"Stock Track | MBX Biosciences Plummets 5.08% Intraday on Negative Earnings Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1151954255","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151954255?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:34","pubTimestamp":1773419667,"startTime":"0","endTime":"0","summary":"MBX Biosciences' stock price plummeted 5.08% during intraday trading on Friday, as the company faces negative earnings expectations ahead of its upcoming financial report.According to recent earnings...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619192298","title":"MBX Biosciences Inc  expected to post a loss of 58 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619192298","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619192298?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:35","pubTimestamp":1773405325,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc  expected to post a loss of58cents a share - Earnings Preview MBX Biosciences Inc MBX.OQ MBX.O is expected to  show no change in quarterly revenue when it reports  results on May 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N40115X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618134286","title":"MBX Biosciences Inc. publishes corporate presentation on endocrine and metabolic peptide drug development pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134286?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:29","pubTimestamp":1773318572,"startTime":"0","endTime":"0","summary":"MBX said it had USD 459.1 million in pro forma cash and investments as of Dec. 31, 2025, and stated this provides runway into 2029. The company said it expects an Avail Phase 2 presentation with one-year open-label extension data for canvuparatide  in Q2 2026 and plans to initiate a Phase 3 trial in Q3 2026. MBX said Phase 1 12-week multiple ascending dose results for MBX 4291 are anticipated in Q4 2026. The company also said it plans to nominate a development candidate for MBX 5XXX in Q2 2026 and for MBX 6XXX in Q3 2026. MBX said results from the STEADI Phase 2a trial of imapextide  are anticipated in Q2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDLbnskQt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618663134","title":"Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2618663134","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618663134?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:16","pubTimestamp":1773317772,"startTime":"0","endTime":"0","summary":"Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618134353","title":"MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134353","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134353?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:14","pubTimestamp":1773317640,"startTime":"0","endTime":"0","summary":"MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.68) by 27.84 percent. This is a 4.26 percent decrease over losses of $(0.47) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51209331/mbx-biosciences-q4-eps-0-49-beats-0-68-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131001","title":"MBX Biosciences FY 2025 net loss rose 40% to USD 86.97 million, while G&A expenses jumped 75% to USD 18.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131001","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131001?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:05","pubTimestamp":1773317106,"startTime":"0","endTime":"0","summary":"MBX Biosciences reported a Q4 net loss of USD 22.06 million, up 42% year over year. Q4 R&D expense rose 30% to USD 19.76 million, driven by costs for the MBX 4291 Phase 1 trial, the canvuparatide Phase 2 Avail trial and Phase 3 preparation activities. Q4 G&A expense increased 78% to USD 6.04 million, reflecting higher personnel-related costs and professional fees as a public company. For FY 2025, net loss widened 40% to USD 86.97 million, while R&D expense increased 38% to USD 79.16 million. MBX said pro forma cash and investments were USD 459.1 million as of Dec. 31, 2025, including USD 85.4 million of net proceeds raised through its ATM facility, and expects this to fund operations into 2029.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL3sjqbM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD","NDAQ","BK4007","IE00B3QW5Z07.USD","BK4585","MBX","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618213178","title":"Press Release: MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2618213178","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618213178?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316800,"startTime":"0","endTime":"0","summary":"Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA. 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026. Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026. $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029. \"2025 was a year of continued growth and execution for MBX, highlighted by the clinical validation of our Precision Endocrine Peptide  platform,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"Following a successful End-of-Phase 2 meeting with the FDA, we now have a clear path to initiate our Phase 3 trial of once-weekly canvuparatide. We are also advancing a growing obesity p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","TM","HP","PBH","BK4092","BK4604","BK4099","BK4555","BK4007","MBX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618937058","title":"Mbx Biosciences Appoints Karen Basbaum as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937058?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144008,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUABM80XR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618693702","title":"Press Release: MBX Biosciences Appoints Karen Basbaum as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618693702","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618693702?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144000,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., March 10, 2026  -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Karen Basbaum, MBA, as Chief Business Officer . Ms. Basbaum brings more than two decades of leadership in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries.\"Karen is a highly accomplished and strategic leader with a proven track record of sourcing, structuring, and executing high-value partnerships, financings, and mergers and acquisitions that create long-term shareholder value,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"Her experience executing complex, value-creating agreements with major global pharmaceutical companies will be instrumental as we advance our pipeline and pursue strategic opp","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4092","BK4099","PBH","BK4604","MBX","BK4555","TM","HP","BK4588","BK4007","BK4585","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618930338","title":"Microbix Advances Modernized Manufacturing for Kinlytic Clot-Buster Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2618930338","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618930338?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:51","pubTimestamp":1773143506,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) just unveiled an announcement. Microbix Biosystems and its U.S. commercialization partner Sequel Pharma have adva...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-advances-modernized-manufacturing-for-kinlytic-clot-buster-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-advances-modernized-manufacturing-for-kinlytic-clot-buster-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625631","title":"MBX Biosciences plans Q3 2026 Phase 3 trial for once-weekly canvuparatide in hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625631","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625631?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:04","pubTimestamp":1773057844,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL4hXwNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618623009","title":"Mbx Biosciences Inc - to Initiate Phase 3 Trial for Canvuparatide in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623009?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:00","pubTimestamp":1773057601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA2GBQS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":113,"code":"91000000","status":"200"}]}}